Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB1 | P20618 | 5/20 | 0.61 |
| ▸ | PSMB5 | P28074 | 5/20 | 0.61 |
| ▸ | PSMB2 | P49721 | 4/20 | 0.61 |
| ▸ | LTA4H | P09960 | 1/20 | 0.60 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.56 |
| ▸ | ESR1 | P03372 | 2/20 | 0.54 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | THRB | P10828 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.54 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.54 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.54 |
| ▸ | DRD4 | P21917 | 1/20 | 0.54 |
| ▸ | ACHE | P22303 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5728349 | 0.84 | L3MBTL1 (0.60) | PSMB1PSMB5PSMB2LTA4HHRH3 | |
| SCHEMBL10685703 | 0.83 | LTA4H (0.70) | PSMB1PSMB5PSMB2LTA4HHRH3 | |
| SCHEMBL10676277 | 0.82 | LTA4H (0.71) | PSMB1PSMB5PSMB2LTA4HESR1 | |
| SCHEMBL7209622 | 0.81 | L3MBTL1 (0.58) | PSMB1PSMB5PSMB2LTA4HHRH3 | |
| SCHEMBL5725869 | 0.80 | NR4A2 (0.54) | MAPTSMN1; SMN2 | |
| SCHEMBL7140961 | 0.80 | MCHR1 (0.73) | PSMB1PSMB5LTA4HHRH3MCHR1 | |
| SCHEMBL5175148 | 0.78 | LTA4H (0.73) | PSMB1PSMB5PSMB2LTA4HHRH3 | |
| SCHEMBL14287617 | 0.77 | SMN1; SMN2 (0.76) | PSMB1PSMB5PSMB2HRH3ALDH1A1 | |
| SCHEMBL13305534 | 0.77 | LTA4H (0.97) | PSMB1PSMB5PSMB2LTA4HESR1 | |
| SCHEMBL1358544 | 0.77 | PSMB1 (0.78) | PSMB1PSMB5PSMB2LTA4HHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1705169-A2 | Triphenylalkene derivatives and their use as selective estrogen receptor modulators | Hormos Medical Ltd. (FI) | 2006-09-27 | — | — | EP | disclosed |
| EP-1235776-B1 | TRIPHENYLALKENE DERIVATIVES AND THEIR USE AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | HORMOS MEDICAL CORP (FI) | 2006-02-08 | — | — | EP | disclosed |
| US-6875775-B2 | Triphenylalkene derivatives and their use as selective estrogen receptor modulators | HORMOS MEDICAL OY LTD (FI) | 2005-04-05 | — | — | US | disclosed |
| US-20030225130-A1 | Triphenylalkene derivatives and their use as selective estrogen receptor modulators | HORMOS MEDICAL OY LTD. | 2003-12-04 | — | — | US | disclosed |
| US-6576645-B1 | Such as 3-(4-chloro-1-(4-(2-(2-hydroxyethoxy)ethoxy)phenyl)--2-phenylbut-1 -enyl)phenol; producing tissue specific estro-genic and/or antiestrogenic effect | HORMOS MEDICAL OY LTD (FI) | 2003-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225130-A1 | Triphenylalkene derivatives and their use as selective estrogen receptor modulators | ESR2, ESR1, GPER1 | PSMB1 2238/4885PSMB5 1936/4885PSMB2 1710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.